Abstract:Our understanding of inherited retinal disease has benefited immensely from molecular genetic analysis over the past several decades. New technologies that allow for increasingly detailed examination of a patient's DNA have expanded the catalog of genes and specific variants that cause retinal disease. In turn, the identification of pathogenic variants has allowed the development of gene therapies and low-cost, clinically focused genetic testing. Despite this progress, a relatively large fraction (at least 20%) of patients with clinical features suggestive of an inherited retinal disease still do not have a molecular diagnosis today. Variants that are not obviously disruptive to the codon sequence of exons can be difficult to distinguish from the background of benign human genetic variations. Some of these variants exert their pathogenic effect not by altering the primary amino acid sequence, but by modulating gene expression, isoform splicing, or other transcript-level mechanisms. While not discoverable by DNA sequencing methods alone, these variants are excellent targets for studies of the retinal transcriptome. In this review, we present an overview of the current state of pathogenic variant discovery in retinal disease and identify some of the remaining barriers. We also explore the utility of new technologies, specifically patient-derived induced pluripotent stem cell (iPSC)-based modeling, in further expanding the catalog of disease-causing variants using transcriptome-focused methods. Finally, we outline bioinformatic analysis techniques that will allow this new method of variant discovery in retinal disease. As the knowledge gleaned from previous technologies is informing targets for therapies today, we believe that integrating new technologies, such as iPSC-based modeling, into the molecular diagnosis pipeline will enable a new wave of variant discovery and expanded treatment of inherited retinal disease.

Preclinical alternative drug discovery programs for monogenic rare diseases. The case of hereditary spastic paraplegias

Pluripotent Stem Cells as a Preclinical Cellular Model for Studying Hereditary Spastic Paraplegias

Personalized Treatment for Infantile Ascending Hereditary Spastic Paralysis Based on In Silico Strategies

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes

Hereditary spastic paraplegias proteome: common pathways and pathogenetic mechanisms

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

[Rare diseases: unraveling the biological bases to find future therapies]

Decoding Hereditary Spastic Paraplegia Pathogenicity Through Transcriptomic Profiling

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST

Pharmacological rescue of mitochondrial and neuronal defects in SPG7 hereditary spastic paraplegia patient neurons using high throughput assays

Quantitative Systems Pharmacology Models: Potential Tools for Advancing Drug Development for Rare Diseases

Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47

Antisense oligonucleotides and their applications in rare neurological diseases

Patient derived stem cells for discovery and validation of novel pathogenic variants in inherited retinal disease

Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?

Rare diseases: Insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis

Treatment of hereditary amyotrophic lateral sclerosis

High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia

Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?